Europese Unie - Nederlands - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porfyrie, de lever - verschillende maagdarmkanaal en metabolisme producten - behandeling van acute hepatische porfyrie (ahp) bij volwassenen en adolescenten van 12 jaar en ouder.

Europese Unie - Nederlands - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - andere maagdarmkanaal en metabolisme producten, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Europese Unie - Nederlands - EMA (European Medicines Agency)

advanz pharma limited - obeticholic zuur - levercirrose, gal - gal en levertherapie - ocaliva is geïndiceerd voor de behandeling van primaire biliaire acute cholangitis (ook bekend als primaire biliaire cirrose) in combinatie met ursodeoxycholic zuur (udca) bij volwassenen met een onvoldoende reactie op udca of als monotherapie bij volwassenen kunnen tolereren udca.

Europese Unie - Nederlands - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran natrium - amyloïdose, familiaire - andere medicijnen voor het zenuwstelsel - onpattro is geïndiceerd voor de behandeling van erfelijke transthyretine-gemedieerde amyloïdose (hattr amyloïdose) bij volwassen patiënten met fase 1 of fase 2 polyneuropathie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoom, plaveiselcel - antineoplastische middelen - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastische middelen - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Europese Unie - Nederlands - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andere medicijnen voor het zenuwstelsel - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.